- Home
- TBCV vs RLMD Comparison
TBCV vs RLMD Comparison
Compare TBCV & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TBCV | RLMD |
|---|---|---|
| Founded | 2024 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 373.9M | 348.8M |
| IPO Year | 2026 | 2012 |
Fundamental Metrics
Financial Performance| Metric | TBCV | RLMD |
|---|---|---|
| Price | $9.78 | $4.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 4.6K | ★ 1.6M |
| Earning Date | N/A | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $9.77 | $2.42 |
| 52 Week High | $9.84 | $8.00 |
Technical Indicators
Market Signals| Indicator | TBCV | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 43.72 | 66.19 |
| Support Level | N/A | $4.00 |
| Resistance Level | $9.84 | $4.35 |
| Average True Range (ATR) | 0.02 | 0.21 |
| MACD | -0.00 | 0.12 |
| Stochastic Oscillator | 0.00 | 92.24 |
Price Performance
Historical ComparisonAbout TBCV Thunder Bridge Capital Partners V Ltd. Class A Ordinary Shares
Thunder Bridge Capital Partners V Ltd is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.